-
Completion of the Clinical Research on Knee Osteoarthritis using “MicoCell™” 3D Cell Culture Vessel -Safety of Cell Aggregates Confirmed at our Collaborative Research Clinic-
-
Participation in the Innovative Next Generation of Oligonucleotide Therapeutics Project conducted by AMED
-
Price increase for Superabsorbent Polymers
-
- Management and Business
- Sustainability
Nippon Shokubai Obtains ISCC PLUS for Superabsorbent Polymers Derived from Caustic Soda Produced from Renewable Energy -Contributing to the reduction of the environmental impact of disposable diapers-
-
Notice of Organizational Reform (As of April 1st, 2022) – Changing Our Organizational Structure to Promote Our Three Transformations –
-
Notice of Revisions to Earnings Forecasts and Dividends Forecasts for the Fiscal Year ending March 31, 2022
-
Summary of Consolidated Financial Results For the Third Quarter of the Fiscal Year Ending March 31, 2022 [IFRS]
-
Development of a Coating Material with High Antiviral Effect! – The Inactivation of Human Coronavirus through the New Coating Material –
-
New Year’s Message 2022
-
Nippon Shokubai published “TechnoAmenity Report 2021”, “Financial Section 2021” and “RC Report 2021.”
-
Targeting Carbon Neutrality in 2050: Aiming for a 30% Reduction in CO2 Emissions by 2030
-
Financial Results Briefing Material, Q2-FY2021
-
Summary of Consolidated Financial Results For the Second Quarter of the Fiscal Year Ending March 31, 2022 [IFRS]
-
Notice of Revisions to Earnings Forecasts for the Fiscal Year ending March 31, 2022
-
Notice to stop the old facilities of superabsorbent polymers
-
Development of an antibacterial and antiviral graphene oxide composite membrane with high water resistance – Inactivating various bacteria and viruses including SARS-CoV-2, to improve wet area sanitation –
-
Price increase for Superabsorbent Polymers
-
Joint Study to Commence on the Supply of Ethylene Derivatives derived from Bio-based Raw Materials
-
Notice of Revisions to Earnings Forecasts and Dividends Forecasts for the Fiscal Year ending March 31, 2022
-
Summary of Consolidated Financial Results For the First Quarter of the Fiscal Year Ending March 31, 2022 [IFRS]